Jones DR - Search Results

1

Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N. Kolwankar D, et al. Among authors: jones dr. Clin Gastroenterol Hepatol. 2007 Mar;5(3):388-93. doi: 10.1016/j.cgh.2006.12.021. Clin Gastroenterol Hepatol. 2007. PMID: 17368239

2

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

Wang YH, Jones DR, Hall SD. Wang YH, et al. Among authors: jones dr. Drug Metab Dispos. 2004 Feb;32(2):259-66. doi: 10.1124/dmd.32.2.259. Drug Metab Dispos. 2004. PMID: 14744949

3

Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples.

Vuppalanchi R, Cummings OW, Saxena R, Ulbright TM, Martis N, Jones DR, Bansal N, Chalasani N. Vuppalanchi R, et al. Among authors: jones dr. J Clin Gastroenterol. 2007 Feb;41(2):206-10. doi: 10.1097/01.mcg.0000225515.28536.3a. J Clin Gastroenterol. 2007. PMID: 17245221

4

Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis.

Vuppalanchi R, Liang T, Goswami CP, Nalamasu R, Li L, Jones D, Wei R, Liu W, Sarasani V, Janga SC, Chalasani N. Vuppalanchi R, et al. PLoS One. 2013 Sep 13;8(9):e74471. doi: 10.1371/journal.pone.0074471. eCollection 2013. PLoS One. 2013. PMID: 24058572 Free PMC article.

5

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Williams JA, et al. Among authors: jones dr. Drug Metab Dispos. 2002 Aug;30(8):883-91. doi: 10.1124/dmd.30.8.883. Drug Metab Dispos. 2002. PMID: 12124305

6

Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

Ernest CS 2nd, Hall SD, Jones DR. Ernest CS 2nd, et al. Among authors: jones dr. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91. doi: 10.1124/jpet.104.075416. Epub 2004 Nov 2. J Pharmacol Exp Ther. 2005. PMID: 15523003

7

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.

Wang YH, Jones DR, Hall SD. Wang YH, et al. Among authors: jones dr. Drug Metab Dispos. 2005 May;33(5):664-71. doi: 10.1124/dmd.104.001834. Epub 2005 Feb 2. Drug Metab Dispos. 2005. PMID: 15689501

8

Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.

Dennison JB, Jones DR, Renbarger JL, Hall SD. Dennison JB, et al. Among authors: jones dr. J Pharmacol Exp Ther. 2007 May;321(2):553-63. doi: 10.1124/jpet.106.118471. Epub 2007 Feb 1. J Pharmacol Exp Ther. 2007. PMID: 17272675

9

Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5).

Jones DR, Ekins S, Li L, Hall SD. Jones DR, et al. Drug Metab Dispos. 2007 Sep;35(9):1466-75. doi: 10.1124/dmd.106.014613. Epub 2007 May 30. Drug Metab Dispos. 2007. PMID: 17537872

10

Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.

Zhang X, Jones DR, Hall SD. Zhang X, et al. Among authors: jones dr. Drug Metab Dispos. 2009 Jan;37(1):150-60. doi: 10.1124/dmd.108.022178. Epub 2008 Oct 14. Drug Metab Dispos. 2009. PMID: 18854379

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,430 results

Search Page

Filters